首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Immunology Immunotherapy

Cancer Immunology Immunotherapy杂志,由Springer Berlin Heidelberg出版,于1976年创刊,Monthly,出版语言English,ISSN:0340-7004,E-ISSN:1432-0851。

投稿咨询
Cancer Immunology Immunotherapy
Cancer Immunology Immunotherapy
Cancer Immunology Immunotherapy
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
5.8
CiteScore
9.5
期刊收录
SCI、SCIE

Cancer Immunology Immunotherapy(中文译名:《癌症免疫学免疫治疗》),ISSN:0340-7004,EISSN:1432-0851,是Springer Berlin Heidelberg出版的国际性学术期刊,创刊于1976年,以Monthly形式稳定发行,2026年总发文量约359篇。该刊采用非OA开放访问,学科归属为医学 - 免疫学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达5.8,2025年期刊CiteScore为9.5,2025年期刊自引率约3.4%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Cancer Immunology Immunotherapy长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约1月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、GERMANY (FED REP GER)、Japan、Italy、Netherlands、France等为核心发文国家与地区;HELMHOLTZ ASSOCIATIONINSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)、FUDAN UNIVERSITY、EBERHARD KARLS UNIVERSITY OF TUBINGEN、HARVARD UNIVERSITY、RUPRECHT KARLS UNIVERSITY HEIDELBERG、UNIVERSITY OF DUISBURG ESSEN等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学 IMMUNOLOGY 免疫学
2区 2区
否 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
IMMUNOLOGY 免疫学 ONCOLOGY 肿瘤学
3区 3区
否 否

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
IMMUNOLOGY 免疫学 ONCOLOGY 肿瘤学
3区 3区
否 否

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 40 / 183

78.4

学科:ONCOLOGY SCIE Q1 67 / 333

80

学科:IMMUNOLOGY SCIE Q1 35 / 183

81.15

学科:ONCOLOGY SCIE Q1 66 / 333

80.33

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 42 / 183

77.3

学科:ONCOLOGY SCIE Q1 68 / 328

79.4

学科:IMMUNOLOGY SCIE Q1 39 / 183

78.96

学科:ONCOLOGY SCIE Q1 71 / 328

78.51


中国学者近期发文

1
Envafolimab combined with lenvatinib and albumin-bound paclitaxel in previously treated advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: a prospective, phase II, multi-cohort tria

Author:Zhao, Xiaoying; Feng, Wanjing; Geng, Qirong; Huang, Mingzhu; Zhang, Zhe; Chen, Jinsi; Sheng, Xuedan; Zhu, Xiaodong; Guo, Weijian

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04373-4

2
IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphom

Author:Wu, Hui; Zhang, Jiaqing; Xu, Li; Xie, Yifan; Pan, Lingli; Zhang, Xinyue; Xia, Yongming; Yang, Fang; Kang, Xiaozhen; Tong, Xiangmin; Wang, Shibing

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04396-x

3
KSR2 functions as a metabolic checkpoint for anti-PD-1 resistance by reprogramming glucose metabolis

Author:Ge, Yuli; Zhou, Qiong; Zhang, Qiangqiang; Hu, Yanyan; Wang, Rui

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04394-z

4
Promoting APC function of B cells via reprogramming the fatty acid metabolism enhances anticancer immunity in metastatic ovarian cance

Author:Zhang, Haoke; Yu, Chunyan; Du, Wei; Li, Huiyang; Liu, Zihe; Li, Xueying; Yue, Yuhan; Wang, Bo; Wang, Hongmei; Ouyang, Yuqing; Wu, Haixia; Feng, Xiaofan; Yu, Jianchun; Liu, Yaru; Ji, Boyu; Cai, Siyu; Zhang, Hong; Deng, Weimin

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04387-y

5
Hematological toxicities and thrombosis risk associated with immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 202

Author:Hou, Jingyi; Mu, Guangyan; Zhang, Zhuo; Xiang, Qian; Cui, Yimin

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04380-5

6
Hypoalbuminemia induces immunosuppression through disorder in macrophages and drives resistance to immune checkpoint inhibitor

Author:Yang, Fan; Long, Yaping; Li, Yao; Bai, Yibing; Liu, Yining; Cheng, Dingyuan; Li, Tao; Lu, Yiheng; Han, Xiao; Hu, Yi

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04364-5

7
Impact of immunochemotherapy administration sequence on overall survival in advanced esophageal and gastric cancers: a propensity score-matched multicenter analysi

Author:Hang, Junjie; Wu, Lixia; Xiao, Li; Duan, Qiuhua; Zhao, Han; Huang, Junjie; Guo, Jinfeng; Huang, Yiqing; Zhang, Dapeng; Cheng, Gang; Dong, Xiao; Xue, Peng; Chang, Jianhua

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 5, pp. -. DOI: 10.1007/s00262-026-04382-3

8
Integrated spatial transcriptomics and pan-cancer XGBoost modeling uncover spatial drivers of immune exclusion and predict immunotherapy respons

Author:Zhao, Hongying; Liu, Wangyang; Xu, Haotian; Wang, Lu; Chen, Zushun; Sun, Yanwu; Wang, Li

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 4, pp. -. DOI: 10.1007/s00262-026-04374-3

9
Immune checkpoint inhibitor-related myocarditis in patients with thymic epithelial tumors: a retrospective cohort analysi

Author:Zeng, Haiyan; Kang, Jin; Pu, Sijia; Dai, Chang; Jiang, Junrong; Chen, Yanlin; Chen, Yuhan; Fu, Lu; Liu, Huiyi; Guo, Mengmeng; Yi, Hong; Chen, Haowei; Zhong, Wenzhao; Xue, Yumei

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 4, pp. -. DOI: 10.1007/s00262-026-04362-7

10
Metformin drives HIF-1α-mediated dual metabolic reprogramming to enhance γδ T cell therapy in triple-negative breast cance

Author:Qin, Xuping; Zhong, Haowen; Liu, Meize; Yu, Tiantian; Ma, Rong; Zhou, Ying; Chen, Jingyu; Liu, Fen; Wang, Xiwei; Long, Jianting

Journal: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2026; Vol. 75, Issue 4, pp. -. DOI: 10.1007/s00262-026-04351-w


在线咨询

Cancer Immunology Immunotherapy

国际简称:CANCER IMMUNOL IMMUN参考译名:癌症免疫学免疫治疗

年发文量:359 CiteScore:9.5 是否预警:否 Gold OA文章占比:87.15% 研究类文章占比:92.20%

杂志社联系方式:SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013

Cancer Immunology Immunotherapy